Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia

By Ascher-Svanum Haya   Stensland Michael D.   Peng Xiaomei   Faries Douglas E.   Stauffer Virginia L.   Osuntokun Olawale O.   Kane John M.  

Current Medical Research and Opinion, Vol. 27, Iss. 1, 2011-01 ,pp. : 115-122

Informa Healthcare

Access to resources Recommend Favorite

Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data

By Rajagopalan Krithika  

Journal of Medical Economics, Vol. 16, Iss. 7, 2013-07 ,pp. : 951-961

Informa Healthcare

Access to resources Recommend Favorite

A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA)

By Wolf Jürgen   Janssen Firmin   Lublin Henrik   Salokangas Raimo KR   Allain Hervé   Smeraldi Enrico   Bernardo Miguel   Millar Helen   Pans Miranda   Adelbrecht Christine   Laughton Jim   Werner Christian   Maier Wolfgang  

Current Medical Research and Opinion, Vol. 23, Iss. 10, 2007-10 ,pp. : 2313-2323

Informa Healthcare

Access to resources Recommend Favorite

Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK**

By Davies Andrew   Vardeva Kawitha   Loze Jean-Yves   L’’Italien Gilbert J.   Sennfalt Karin   Baardewijk Marc van  

Current Medical Research and Opinion, Vol. 24, Iss. 11, 2008-11 ,pp. : 3275-3285

Informa Healthcare

Access to resources Recommend Favorite

Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off

By Findley Leslie J   Lees Andrew   Apajasalo Marjo   Pitkänen Anna   Turunen Heidi  

Current Medical Research and Opinion, Vol. 21, Iss. 7, 2005-07 ,pp. : 1005-1014

Informa Healthcare

Access to resources Recommend Favorite